EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models

Takashi Kumada iD, Masanori Atsukawa iD, Norio Itokawa iD, Taeang Arai iD, Hidenori Toyoda iD, Akihito Tsubota iD, Tsunamasa Watanabe iD, Makoto Chuma iD, Kentaro Matsuura iD, Atsushi Hiraoka iD, Toshifumi Tada iD, Koichi Takaguchi iD und 10 weitere

Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 345-355

DOI: 10.1111/apt.70704 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 04.05.2026. Verfasst von Takashi Kumada und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan. Hauptthemen laut MEDLINE: Guanine, Tenofovir, Antiviral Agents, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Entecavir and tenofovir alafenamide fumarate are potent nucleos(t)ide analogues used to treat chronic hepatitis B; however, their differential effects on hepatitis B surface antigen expression decline remain unclear. In this multicentre study, we aimed to examine the hepatitis B surface antigen‐reducing effects.

Methods

Treatment‐naïve chronic hepatitis B patients who received entecavir ( n = 491) or tenofovir alafenamide fumarate ( n = 463) were enrolled. After 1:1 propensity score matching for sex, baseline hepatitis B surface antigen, hepatitis B e‐antigen status, hepatitis B virus deoxyribonucleic acid, fibrosis‐4 score, and the presence of hepatocellular carcinoma, data from 334 patients per group were analysed. Linear mixed‐effects models were used to assess longitudinal changes over 4 years.

Results

Tenofovir alafenamide fumarate was associated with a greater decline in hepatitis B surface antigen compared to entecavir, with significant differences at 1, 3, and 4 years. Its superiority was most pronounced in patients aged < 65 years, those without cirrhosis, those with baseline hepatitis B surface antigen ≥ 3.0 log IU/mL, those with either negative or positive hepatitis B e‐antigen, and those with baseline hepatitis B virus deoxyribonucleic acid < 4.4 log IU/mL. Both treatments achieved comparable virological suppression and alanine aminotransferase normalisation. The estimated glomerular filtration rate showed a transient decline with tenofovir alafenamide fumarate in year 1, which subsequently diminished and may partly reflect the inhibition of tubular creatinine secretion.

Conclusions

This evidence supports personalised treatment selection for functional cure. Trial Registration The UMIN Clinical Trials Registry 000034362

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GuanineTenofovirAntiviral AgentsHepatitis B, ChronicAdenineHepatitis B Surface AntigensHumansPropensity ScoreFemaleMiddle AgedAlanineMaleAdultTreatment OutcomeAged

Stichwörter der Autor:innen

chronic hepatitis Bentecavirhepatitis B surface antigenmixed‐effects modelpropensity score matchingsubgroup analysistenofovir alafenamide

Substanzen

entecavirGuanineTenofovirAntiviral AgentsAdenineHepatitis B Surface AntigensAlaninetenofovir alafenamide

Autor:innen und Institutionen

  • Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
  • Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan.

ORCID-Profile: Takashi Kumada, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Hidenori Toyoda, Akihito Tsubota, Tsunamasa Watanabe, Makoto Chuma, Kentaro Matsuura, Atsushi Hiraoka, Toshifumi Tada, Koichi Takaguchi, Joji Tani, Toru Ishikawa, Chikara Ogawa, Toru Asano, Tsunekazu Oikawa, Tomoyuki Akita, Junko Tanaka

Zitieren

APA

Kumada, T., Atsukawa, M., Itokawa, N., Arai, T., Toyoda, H., Tsubota, A., Watanabe, T., Chuma, M., Matsuura, K., Hiraoka, A., Tada, T., Takaguchi, K., Kato, K., Abe, H., Tani, J., Ishikawa, T., Ogawa, C., Asano, T., Oikawa, T., …, & Tanaka, J. (2026). Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models. Alimentary Pharmacology & Therapeutics, 64(3), 345-355. https://doi.org/10.1111/apt.70704

Vancouver

Kumada T, Atsukawa M, Itokawa N, Arai T, Toyoda H, Tsubota A, et al. Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models. Alimentary Pharmacology & Therapeutics. 2026;64(3):345-355. doi:10.1111/apt.70704

BibTeX
@article{Kumada2026,
  author = {Kumada, Takashi and Atsukawa, Masanori and Itokawa, Norio and Arai, Taeang and Toyoda, Hidenori and Tsubota, Akihito and Watanabe, Tsunamasa and Chuma, Makoto and Matsuura, Kentaro and Hiraoka, Atsushi and Tada, Toshifumi and Takaguchi, Koichi and Kato, Keizo and Abe, Hiroshi and Tani, Joji and Ishikawa, Toru and Ogawa, Chikara and Asano, Toru and Oikawa, Tsunekazu and Matsumoto, Yoshihiro and Akita, Tomoyuki and Tanaka, Junko},
  title = {Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {3},
  pages = {345--355},
  doi = {10.1111/apt.70704}
}
Kostenlos starten →